A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis

Circulation Research

Volumn 86, Issue 4, 2000, Pages 391-395

  Cahilly, Carolyn ^a   Ballantyne, Christie M ^a   Lim, Do Sun ^a   Gotto, Antonio ^b   Marian, Ali J ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Section of Cardiology   (United States)

Author keywords

Atherosclerosis; Coronary disease; Genetics; Polymorphism; Reactive oxygen species

Indexed keywords

FLUINDOSTATIN; HISTIDINE; LIPID; REACTIVE OXYGEN METABOLITE; TYROSINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE SEVERITY; GEL ELECTROPHORESIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MUTATION; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0034599040     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.86.4.391     Document Type: Article

References (35)

1. Steinberg D. At last, direct evidence that lipoxygenases play a role in atherogenesis. J Clin Invest. 1999;103:1487-1488.
2. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997;337:408-416.
3. Sena CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 1996;10:709-720.
4. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res. 1992;70: 593-599.
5. 2 in angiotensin H-induced vascular hypertrophy. Hypertension. 1998;32:488-495.
6. Li PF, Dietz R, von Harsdorf R. Reactive oxygen species induce apoptosis of vascular smooth muscle cell. FEBS Lett. 1997;404:249-252.
7. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 1999;99: 2934-2941.
8. Li AE, Ito H, Rovira II, Kim KS, Takeda K, Yu ZY, Ferrans VJ, Finkel T. A role for reactive oxygen species in endothelial cell anoikis. Circ Res. 1999;85:304-310.
9. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547-1560.
10. Steinberg D. Low-density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
11. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
12. Babior BM. NADPH oxidase: an update. Blood. 1999;93:1464-1476.
13. Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol. 1994;266(6 pt 2):H2568-H2572.
14. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996;98:2572-2579.
15. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci U S A. 1997;94:14483-14488.
16. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol. 1996;271(4 pt 2):H1626-H1634.
17. Knoller S, Shpungin S, Pick E. The membrane-associated component of the amphiphile-activated, cytosol-dependent superoxide-forming NADPH oxidase of macrophages is identical to cytochrome b559. J Biol Chem. 1991;266:2795-2804.
18. phox is required for activation of the NADPH oxidase. J Biol Chem. 1996;271:22152-22158.
19. phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996;271:23317-23321.
20. Dinauer MC, Pierce EA, Bruns GAP, Curnutte JT, Orkin SH. Human neutrophil cytochrome b light chain (p22-phox): gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest. 1990;86: 1729-1737.
21. de Boer M, de Klein A, Hossle JP, Seger R, Corbeel L, Weening RS, Roos D. Cytochrome b558-negative, autosomal recessive chronic granulomatous disease: two new mutations in the cytochrome b558 light chain of the NADPH oxidase (p22-phox). Am J Hum Genet. 1992;51: 1127-1135.
22. Porter CD, Parker MH, Kinnon C. Identification of a donor splice site mutation leading to loss of p22-phox exon 5 in autosomal chronic granulomatous disease. Hum Mutat. 1996;7:374.
23. Leusen JH, Bolscher BG, Hilarius PM, Weening RS, Kaulfersch W, Seger RA, Roos D, Verhoeven AJ. 156Pro→Gln substitution in the light chain of cytochrome b558 of the human NADPH oxidase (p22-phox) leads to defective translocation of the cytosolic proteins p47-phox and p67-phox. J Exp Med. 1994;180:2329-2334.
24. Hossle JP, de Boer M, Seger RA, Roos D. Identification of allele-specific p22-phox mutations in a compound heterozygous patients with chronic granulomatous disease by mismatch PCR and restriction enzyme analysis. Hum Genet. 1994;93:437-442.
25. Parkos CA, Dinauer MC, Walker LE, Allen RA, Jesaitis AJ, Orkin SH. Primary structure and unique expression of the 22-kilodalton light chain of human neutrophil cytochrome b. Proc Natl Acad Sci U S A. 1988;85:3319-3323.
26. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation. 1998;97:135-137.
27. Li A, Prasad A, Mincemoyer R, Satorius C, Epstein N, Finkel T, Quyyumi AA. Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. Am J Med Genet. 1999;86:57-61.
28. Cai H, Duarte N, Wilcken DE, Wang XL. NADH/NADPH oxidase p22 phox C242T polymorphism and coronary artery disease in the Australian population. Eur J Clin Invest. 1999;29:744-748.
29. West MS, Herd JA, Ballantyne CM, Pownall HJ, Simpson S, Gould L, Gotto AM Jr, for the LCAS Investigators. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996;17:550-583.
30. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West MS, Gould KL, Gotto AM Jr, for the LCAS Investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997;80:278-286.
31. Landers ES, Schork NJ. Genetic dissection of complex traits. Science. 1994;265:2037-2048.
32. phox in human coronary arteries. Circulation. 1999;100:1494-1498.
33. phox based NADH oxidase in vascular smooth muscle. Biochem J. 1998;329:653-657.
34. Griendling KK, Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. J Lab Clin Med. 1998;132:9-15.
35. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Bräsen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Böhm M, Meinertz T, Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis. Circulation. 1999;99:2027-2033.